看之前记得先点个关注,欢迎投稿共创。药圈观察局,最新观察:本文为共创内容,作者:#药圈观察局2组在经历数年亏损与市场质疑后,植发第一股雍禾医疗于2026年3月3日发布了一份正面盈利预告,宣告其战略转型进入收获期。公告显示,雍禾医疗预计2025年度净利润不少于人民币7000万元,相较于2024年度高达2.27亿元的亏损,成功实现扭亏为盈,一年时间完成了超过2.9亿元的利润跨越。(全年营收预计16亿...
Source Link看之前记得先点个关注,欢迎投稿共创。药圈观察局,最新观察:本文为共创内容,作者:#药圈观察局2组在经历数年亏损与市场质疑后,植发第一股雍禾医疗于2026年3月3日发布了一份正面盈利预告,宣告其战略转型进入收获期。公告显示,雍禾医疗预计2025年度净利润不少于人民币7000万元,相较于2024年度高达2.27亿元的亏损,成功实现扭亏为盈,一年时间完成了超过2.9亿元的利润跨越。(全年营收预计16亿...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.